Highly sensitive system and method for analysis of troponin
원문보기
IPC분류정보
국가/구분
United States(US) Patent
등록
국제특허분류(IPC7판)
G01N-033/68
G01N-021/64
G01N-033/58
출원번호
US-0921553
(2015-10-23)
등록번호
US-9719999
(2017-08-01)
발명자
/ 주소
Goix, Philippe J.
Puskas, Robert
Todd, John
Livingston, Richard
Held, Douglas
Wu, Allan H. B.
출원인 / 주소
Singulex, Inc.
대리인 / 주소
McDonnell Boehnen Hulbert & Berghoff LLP
인용정보
피인용 횟수 :
0인용 특허 :
143
초록
The invention provides methods, compositions, kits, and systems for the sensitive detection of cardiac troponin. Such methods, compositions, kits, and systems are useful in diagnosis, prognosis, and determination of methods of treatment in conditions that involve release of cardiac troponin.
대표청구항▼
1. A method for determining an absence of coronary artery disease (CAD) in a subject, the method comprising: (a) measuring the concentration of at least one of Troponin I (cTnI) and cardiac troponin T (cTnT) in a blood, serum or plasma sample from the subject in an assay comprising counting individu
1. A method for determining an absence of coronary artery disease (CAD) in a subject, the method comprising: (a) measuring the concentration of at least one of Troponin I (cTnI) and cardiac troponin T (cTnT) in a blood, serum or plasma sample from the subject in an assay comprising counting individual digital events representing binding of a binding partner the at least one of cTnI and cTnT, wherein each individual digital event comprises a signal representing a single molecule of the cTnI and cTnT in the sample, determining a total signal as a sum of the individual digital events, and relating the sum to the concentration of the at least one of cTnI and cTnT in the sample,(b) determining an absence of CAD in the subject when the concentration of the at least one of cTnI and cTnT in the sample is less than about 10 pg/mL. 2. The method of claim 1, wherein the subject has a symptom of coronary artery disease. 3. The method of claim 2, wherein the symptom is at least one of chest pain, shortness of breath, arm pain, abnormal EKG, and abnormal enzyme levels. 4. The method of claim 1, wherein the CAD is selected from at least one of acute myocardial infarction, cardiac damage, cardiac toxicity, acute coronary syndrome, myocarditis, and heart failure. 5. The method of claim 1, wherein the absence of CAD is determined when the at least one of cTnI and cTnT in the sample is less than about 9 pg/mL. 6. The method of claim 1, wherein the absence of CAD is determined when the at least one of cTnI and cTnT in the sample is less than about 8 pg/mL. 7. The method of claim 1, wherein the absence of CAD is determined when the at least one of cTnI and cTnT in the sample is less than about 7 pg/mL. 8. The method of claim 1, wherein the sample is taken during a stress test. 9. The method of claim 1, wherein the sample is taken after a stress test. 10. The method of claim 1, wherein the assay has a limit of detection for the at least one of cTnI and cTnT of less than 3 pg/mL and a coefficient of variation of less than 10%. 11. The method of claim 1, wherein the binding partner comprises an antibody specific for the at least one of cTnI and cTnT. 12. The method of claim 11, wherein the assay detects a photon emission from a label corresponding to a single molecule of the at least one of cTnI and cTnT in the sample, wherein the antibody is bound to or was bound to a molecule of the at least one of cTnI and cTnT in the sample. 13. The method of claim 12, wherein the antibody is eluted from the at least one of cTnI or cTnT before the photon emission is detected. 14. The method of claim 13, wherein the photon emission is detected in a single molecule analyzer. 15. The method of claim 1, wherein the assay is conducted using an analyzer comprising: (a) an electromagnetic radiation source for stimulating a fluorescent moiety; and(b) an electromagnetic radiation detector that measures an electromagnetic characteristic of the fluorescent moiety when stimulated by the electromagnetic radiation. 16. The method of claim 1, wherein the at least one of Cardiac Troponin I (cTnI) and cardiac troponin T (cTnT) is cTnI. 17. The method of claim 1, wherein the at least one of Cardiac Troponin I (cTnI) and cardiac troponin T (cTnT) is cTnT. 18. A method for determining an absence of coronary artery disease (CAD) in a subject, comprising: (a) measuring the concentration of at least one of Troponin I (cTnI) and cardiac troponin T (cTnT) in a series of blood, serum or plasma samples from the subject in an assay comprising counting individual digital events representing binding of a binding partner to the at least one of cTnI and cTnT, wherein each individual digital event comprises a signal representing a single molecule of the cTnI and cTnT in the sample, determining a total signal as a sum of the individual digital events, and relating the sum to the concentration of the at least one of cTnI and cTnT in the sample,(b) determining at least one of a change and a rate of change in the concentration of the at least one of cTnI and cTnT in the series of samples,(c) determining the absence of coronary artery disease when the at least one of the change and the rate of change of the at least one of cTnI and cTnT in the series of samples is less than a predetermined reference change in concentration of less than 1-10 pg/mL or a predetermined reference rate of change in concentration of 2-10 pg/mL. 19. The method of claim 18, wherein the assay has a limit of detection of less than 3 pg/mL for the at least one of cTnI and cTnT. 20. The method of claim 18, wherein the coronary artery disease is at least one of acute myocardial infarction, cardiac damage, cardiac toxicity, acute coronary syndrome, myocarditis, and heart failure. 21. The method of claim 18, wherein the subject has a symptom of coronary artery disease. 22. The method of claim 21, wherein the symptom is at least one of abnormal EKG, abnormal enzyme levels, chest pain, arm pain, and shortness of breath. 23. The method of claim 18, further comprising comparing the concentration of the at least one of cTnI and cTnT to a threshold concentration representing the 99th percentile concentration of the at least of one cTnI and cTnT in a group of normal subjects. 24. The method of claim 23, wherein the threshold concentration is less than 10 pg/mL. 25. The method of claim 23, wherein the threshold concentration is less than about 7 pg/ml. 26. The method of claim 23, wherein the threshold concentration is less than about 8 pg/ml. 27. The method of claim 23, wherein the threshold concentration is less than about 9 pg/ml. 28. The method of claim 23, wherein the threshold concentration is within a range of 1 pg/ml to 10 pg/ml. 29. The method of claim 18, wherein at least one sample of the series of samples is taken during or after a cardiac stress test. 30. The method of claim 18, wherein the series of samples is taken over a period of up to about 30 hours. 31. The method of claim 30, wherein the series of samples is taken at intervals of less than about 4 hours. 32. The method of claim 18, wherein the binding partner comprises an antibody specific for the at least one of cTnI and cTnT. 33. The method of claim 32, wherein the assay detects a photon emission from a label corresponding to a single molecule of the at least one of cTnI and cTnT in the sample, wherein the antibody is bound to or was bound to a molecule of the at least one of cTnI and cTnT in the sample. 34. The method of claim 33, wherein the antibody is eluted from the at least one of cTnI or cTnT before the photon event. 35. The method of claim 33, wherein the photon emission is detected in a single molecule analyzer. 36. The method of claim 18, wherein the assay is conducted using an analyzer comprising: (a) an electromagnetic radiation source for stimulating a fluorescent moiety; and(b) an electromagnetic radiation detector that measures an electromagnetic characteristic of the fluorescent moiety when stimulated by the electromagnetic radiation. 37. The method of claim 18, wherein the at least one of Cardiac Troponin I (cTnI) and cardiac troponin T (cTnT) is cTnI. 38. The method of claim 18, wherein the at least one of Cardiac Troponin I (cTnI) and cardiac troponin T (cTnT) is cTnT. 39. The method of claim 1, wherein the assay has a sensitivity for the at least one of cTnI and cTnT of less than 3 pg/mL. 40. The method of claim 1, wherein the assay has a sensitivity for the at least one of cTnI and cTnT of less than 1 pg/mL. 41. The method of claim 18, wherein the assay has a sensitivity for the at least one of cTnI and cTnT of less than 3 pg/mL. 42. The method of claim 18, wherein the assay has a sensitivity for the at least one of cTnI and cTnT of less than 1 pg/mL. 43. The method of claim 39, wherein the at least one of Cardiac Troponin I (cTnI) and cardiac troponin T (cTnT) is cTnI. 44. The method of claim 40, wherein the at least one of Cardiac Troponin I (cTnI) and cardiac troponin T (cTnT) is cTnI. 45. The method of claim 41, wherein the at least one of Cardiac Troponin I (cTnI) and cardiac troponin T (cTnT) is cTnI. 46. The method of claim 42, wherein the at least one of Cardiac Troponin I (cTnI) and cardiac troponin T (cTnT) is cTnI. 47. The method of claim 2, wherein the at least one of Cardiac Troponin I (cTnI) and cardiac troponin T (cTnT) is cTnI. 48. The method of claim 5, wherein the at least one of Cardiac Troponin I (cTnI) and cardiac troponin T (cTnT) is cTnI. 49. The method of claim 6, wherein the at least one of Cardiac Troponin I (cTnI) and cardiac troponin T (cTnT) is cTnI. 50. The method of claim 7, wherein the at least one of Cardiac Troponin I (cTnI) and cardiac troponin T (cTnT) is cTnI. 51. The method of claim 10, wherein the at least one of Cardiac Troponin I (cTnI) and cardiac troponin T (cTnT) is cTnI. 52. The method of claim 12, wherein the at least one of Cardiac Troponin I (cTnI) and cardiac troponin T (cTnT) is cTnI. 53. The method of claim 19, wherein the at least one of Cardiac Troponin I (cTnI) and cardiac troponin T (cTnT) is cTnI. 54. The method of claim 23, wherein the at least one of Cardiac Troponin I (cTnI) and cardiac troponin T (cTnT) is cTnI. 55. The method of claim 24, wherein the at least one of Cardiac Troponin I (cTnI) and cardiac troponin T (cTnT) is cTnI. 56. The method of claim 25, wherein the at least one of Cardiac Troponin I (cTnI) and cardiac troponin T (cTnT) is cTnI. 57. The method of claim 26, wherein the at least one of Cardiac Troponin I (cTnI) and cardiac troponin T (cTnT) is cTnI. 58. The method of claim 27, wherein the at least one of Cardiac Troponin I (cTnI) and cardiac troponin T (cTnT) is cTnI. 59. The method of claim 28, wherein the at least one of Cardiac Troponin I (cTnI) and cardiac troponin T (cTnT) is cTnI.
연구과제 타임라인
LOADING...
LOADING...
LOADING...
LOADING...
LOADING...
이 특허에 인용된 특허 (143)
Heller Michael J. (Encinitas CA) Tu Eugene (San Diego CA), Active programmable electronic devices for molecular biological analysis and diagnostics.
Chang, Richard K.; Pan, Young-Le; Pinnick, Ronald G.; Hill, Steven C., Aerosol fluorescence spectrum analyzer for rapid measurement of single airborne particles.
Crosby,Peter A.; Morris,Deborah L.; Soane,Mark M., Apparatus and method for risk stratification of patients with chest pain of suspected cardiac origin.
Baer Thomas M. (Mountain View CA) Dietz Louis J. (Mountain View CA) Dubrow Robert S. (San Carlos CA) Hayter Paul G. (Los Altos CA) Hodges Michael (Palo Alto CA) Manian Bala S. (Los Altos Hills CA) Sh, Apparatus and method for volumetric capillary cytometry.
Serena,Joaqu��n; Dāvalos,Antoni; Castellanos,Mar; Castillo,Jos��; Diamond,Cornelius Allen, Cellular fibronectin as a diagnostic marker in stroke and methods of use thereof.
Chow Calvin Y. H. ; Parce John Wallace ; McReynolds Richard J. ; Kennedy Colin B. ; Bousse Luc J., Controller/detector interfaces for microfluidic systems.
Bergmann, Andreas; Morgenthaler, Nils; Papassotiriou, Jana; Struck, Joachim; Ng, Leong L., Diagnosis and risk classification of acute coronary syndrome by means of CT-proET-1 in combination with NT-proBNP.
Bergmann, Andreas; Morgenthaler, Nils; Papassotiriou, Jana; Struck, Joachim; Anker, Stefan, Diagnosis and risk stratification of cardiac insufficiency by means of natriuretic peptides for NYHA I patients.
Valkirs, Gunars E.; Dahlen, Jeffrey R.; Kirchick, Howard J.; Buechler, Kenneth F., Diagnostic markers of stroke and cerebral injury and methods of use thereof.
Hoffman Michael A. (Carmel CA), Fluorescent-particle analyzer with timing alignment for analog pulse subtraction of fluorescent pulses arising from diff.
Wada, H. Garrett; Kopf-Sill, Anne R.; Alajoki, Marja Liisa; Parce, J. Wallace; Wang, Benjamin N.; Chow, Andrea W.; Dubrow, Robert S., Focusing of microparticles in microfluidic systems.
Swedberg Sally A. (Los Altos CA) Kaltenbach Patrick (Bischweier DEX) Witt Klaus E. (Keltern DEX) Bek Fritz (Waldbronn DEX) Mittelstadt Laurie S. (Belmont CA), Fully integrated miniaturized planar liquid sample handling and analysis device.
Dollinger Gavin D. (San Francisco CA) Cunico Robert L. (Hercules CA) Kunitani Michael G. (San Rafael CA), HPLC light scattering detector for biopolymers.
Mathies Richard A. (Contra Costa County CA) Peck Konan (Contra Costa County CA) Stryer Lubert (Santa Clara County CA), High sensitivity fluorescent single particle and single molecule detection apparatus and method.
Ambrose W. Patrick ; Grace W. Kevin ; Goodwin Peter M. ; Jett James H. ; Orden Alan Van ; Keller Richard A., High throughput analysis of samples in flowing liquid.
Goix, Philippe J.; Puskas, Robert; Todd, John; Livingston, Richard A.; Held, Douglas; Wu, Alan, Highly sensitive system and method for analysis of troponin.
Goix, Philippe; Puskas, Robert; Todd, John; Livingston, Richard; Held, Douglas; Wu, Allan H. B., Highly sensitive system and method for analysis of troponin.
Goix, Philippe; Puskas, Robert; Todd, John; Livingston, Richard; Held, Douglas; Wu, Allan H. B., Highly sensitive system and method for analysis of troponin.
Goix, Philippe J.; Puskas, Robert; Todd, John; Livingston, Richard A.; Held, Douglas; Wu, Alan, Highly sensitive system and methods for analysis of troponin.
Bergmann, Andreas; Ernst, Andrea; Hampel, Harald, In vitro multiparameter determination method for the diagnosis and early diagnosis of neurodegenerative disorders.
Witt Klaus E. (Keltern DEX) Kaltenbach Patrick (Bischweier DEX) Bek Fritz (Waldbronn DEX) Swedberg Sally A. (Los Altos CA) Mittelstadt Laurie S. (Belmont CA), Low voltage miniaturized column analytical apparatus and method.
Begg Geoffrey Stephen (Heidelberg AUX) Simpson Richard John (Richmond AUX) Burgess Antony Wilks (Camberwell AUX), Method allowing sequential chemical reactions.
Purvis ; Jr. Norman B. (1010 Lawnview Ct. Franklin TN 37064) Giorgio Todd D. (3608 Westbrook Dr. Nashville TN 37205), Method and apparatus for determining absolute particle size, surface area and volume normalized fluorescence using forwa.
Cherukuri Satyam C. (Cranbury NJ) Demers Robert R. (Cranbury NJ) Fan Zhong H. (Middlesex NJ) Levine Aaron W. (Lawrenceville NJ) McBride Sterling E. (Lawrence Township ; Mercer County NJ) Zanzucchi Pe, Method and system for inhibiting cross-contamination in fluids of combinatorial chemistry device.
Bergmann, Andreas, Method for controlling the therapy of patients suffering from cardiac insufficiency by means of in vitro determination of threshold values of vasoactive peptides.
Bergmann, Andreas; Papassotiriou, Jana; Struck, Joachim; Morgenthaler, Nils; Anker, Stefan, Method for determining amino-terminal proANP in patients having a cardiac disease or being suspected of developing or having a cardiac disease.
Seidel Claus,DEX ; Gunther Rolf,DEX ; Lupke Stefan,DEX, Method for differentiating or detecting particles in a sample by identifying signal segments of time-resolved, optical raw signals from the sample on the basis of single photon detection.
Goix, Philippe J.; Puskas, Robert; Todd, John; Livingston, Richard A.; Held, Douglas, Method for highly sensitive detection of single protein molecules labeled with fluorescent moieties.
Bergmann, Andreas; Struck, Joachim, Method for the determination of the formation of endothelins for medical diagnostic purposes, and antibodies and kits for carrying out such a method.
Bergmann, Andreas; Struck, Joachim, Method for the determination of the formation of endothelins for medical diagnostic purposes, and antibodies and kits for carrying out such a method.
Robotti, Karla M.; Yin, Hongfeng, Methods and using chemico-mechanical microvalve devices for the selective separation of components from multi-component fluid samples.
Buechler,Kenneth F.; McPherson,Paul H., Methods for the assay of troponin I and T and complexes of troponin I and T and selection of antibodies for use in immunoassays.
Bergmann, Andreas; Struck, Joachim; Morgenthaler, Nils G., Methods for the diagnosis and treatment of critically ill patients with endothelin, endothelin agonists and adrenomedullin antagonists.
Kaltenbach Patrick,DEX ; Swedberg Sally A. ; Witt Klaus E.,DEX ; Bek Fritz,DEX ; Mittelstadt Laurie S., Miniaturized planar columns for use in a liquid phase separation apparatus.
Kaltenbach Patrick (Bischweier DEX) Swedberg Sally A. (Los Altos CA) Witt Klaus E. (Keltern DEX) Bek Fritz (Waldbronn DEX) Mittelstadt Laurie S. (Belmont CA), Miniaturized planar columns in novel support media for liquid phase analysis.
Bottomley Paul A. (Clifton Park NY) Edelstein William A. (Schenectady NY), NMR Imaging of the transverse relaxation time using multiple spin echo sequences.
Hollis Mark A. (Concord MA) Ehrlich Daniel J. (Lexington MA) Murphy R. Allen (Boxboro MA) Kosicki Bernard B. (Acton MA) Rathman Dennis D. (Ashland MA) Chen Chang-Lee (Sudbury MA) Mathews Richard H. (, Optical and electrical methods and apparatus for molecule detection.
Goodwin Peter M. ; Jett James H. ; Keller Richard A. ; Van Orden Alan K. ; Machara Nicholas P., Single molecule identification using selected fluorescence characteristics.
Hugo Katus DE; Anneliese Borgya DE; Klaus Hallermayer DE; Siegfried Looser DE, Specific antibodies to troponin T, their production and use in a reagent for the determination of myocardial necrosis.
Galambos, Paul C.; Okandan, Murat; Montague, Stephen; Smith, James H.; Paul, Phillip H.; Krygowski, Thomas W.; Allen, James J.; Nichols, Christopher A.; Jakubczak, II, Jerome F., Surface-micromachined microfluidic devices.
Doth Margit,DEX ; Petry Christoph,DEX, Synthetic calibrators for use in immunoassays, comprising the analytes or partial sequences thereof which are conjugated to inert carrier molecules.
Myers Stephen A. (25 Nimitz Pl. Old Greenwich CT 06870), System and method for determining changes in fluorescence of stained nucleic acid in electrophoretically separated bands.
Muller Ralph,DEX ; Sauer Markus,DEX ; Zander Christoph,DEX, System for distinguishing fluorescent molecule groups by time resolved fluorescence measurement.
Zeiher, Andreas M.; Heeschen, Christopher; Dimmeler, Stefanie; Hamm, Christian, sCD40L and placental growth factor (PLGF) used as a biochemical marker combination in cardiovascular diseases.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.